ICAR signs tech transfer pact with Biovet for lumpy skin disease vaccine

India will need around 18-20 crore the indigenous lumpy vaccine doses to completely cover all the cattle population which is estimated to be around 193 million in a year

Photo: Bloomberg
Premium

The immunity induced by homologous live-attenuated LSD vaccines usually persists for a minimum period of one year (Photo: Bloomberg)

Sanjeeb Mukherjee New Delhi
In a major step, the Indian Council of Agriculture Research (ICAR) has recently entered into an agreement with Biovet Private Ltd. for the commercial production of the indigenous vaccine of Lumpy Skin Disease (LSD) called ‘Lumpi-ProVacind’.

The agreement for transfer of technology is the first of the series of tie-ups that Agrinnovate which is the commercial arm of ICAR has lined up for grant of non-exclusive license of ‘Lumpi-ProVacind’.

Others in the pipeline according to senior scientists are Hester Biosciences Ltd, Indian Immunological Ltd (IIL), which is an arm of NDDB, Haryana Veterinary Vaccine Institute and an organisation in Maharashtra to manufacture

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 18 2022 | 10:38 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com